Ziltivekimab  (Synonyms: COR-001)

Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Ziltivekimab (皮下注射，每 4 周 1 次 共 24 周) 可显著降低参与刺激动脉粥样硬化血栓形成过程的各种生物标志物 (如 hsCRP (高敏C反应蛋白)、纤维蛋白原、血清淀粉样蛋白 A、结合珠蛋白、分泌型磷脂酶 A2 和脂蛋白 (a))，这些标志物也与全身炎症相关^[4]。

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2226654-05-1

Liquid

Colorless to light yellow

[Ziltivekimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded Ziltivekimab on AHC2 biosensor, can bind IL-6 Protein, Human (N-His, HY-P7044B) with an affinity constant of 5.234E-10 M as determined in BLI assay.
• 
  Immobilized Human IL-6 Protein can bind Ziltivekimab. The EC₅₀ for this effect is 12.41 ng/mL.

• [1]. Kristen L Nowak, et al. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD. Kidney360. 2020 Dec 4;2(2):224-235.  [Content Brief]

  [2]. Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021 Sep 28;117(11):e138-e140.  [Content Brief]

  [3]. Gluba-Brzózka A, et al. Emerging Anti-Atherosclerotic Therapies. Int J Mol Sci. 2021 Nov 9;22(22):12109.  [Content Brief]